Oglesby A, et al. Patient-reported outcomes after switching to a two-drug regimen of dolutegravir + rilpivirine: Week 100 results from the SWORD-1 and SWORD-2 studies. Abstract P101. HIV/Drug Therapy Glasgow 2018.
Effectiviteit en veiligheid van 104 weken subcutaan lenacapavir bij multiresistente hiv-1
jul 2025 | HIV, Virale infecties